Alvotech and JAMP Pharma have entered into an agreement for an exclusive partnership to supply and commercialize five biosimilar candidates in the Canadian market. The current market value of the branded sales for these biosimilars is estimated to exceed $2 billion annually.
 
The partnership agreement includes the exclusive rights for JAMP Pharma to commercialize Alvotech’s biosimilars in Canada, leveraging JAMP’s sales and marketing capabilities and experience in successfully bringing new biosimilars to the fast-growing Canadian market. Under the terms of the agreement, Alvotech will be responsible for full development and commercial supply of the biosimilars from their new state-of-the-art manufacturing facility in Reykjavik, Iceland.
 
“We are very excited and proud to announce our partnership agreement with JAMP,” said Mark Levick, chief executive officer, Alvotech. “With JAMP’s strong commercial background and experience within the Canadian market, we have further opened our network to help realize our continued goals, which is to benefit patients and give them access to high quality biosimilar medicines.  We look forward to working with JAMP in achieving our milestones and setting a new standard in biosimilars.”
 
Louis Pilon, chief executive officer, JAMP Pharma Group, said, “We are thrilled with this partnership, as it will allow the JAMP Pharma Group to become a major player and partner in this market while continuing to expand our traditional generic portfolio, which should surpass 500 products by 2022. We now have six biosimilars in our short-term new product pipeline, and this will have a positive impact on both the company’s future and patient access to these important medicines. The JAMP Pharma Group continues to be driven by our desire to offer more affordable options to Canadian patients.”